The Administrative Core, directed by Dr. Hagop Kantarjian, provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are: Oversee all SPORE activities, in particular the research activities Promote integration and communication between the SPORE, the Leukemia Program, and the Cancer Center Support (Core) Grant Ensure compliance with institutional, governmental, and NCI regulations Assume responsibility for coinmunications and consultations with the NCI project officer and other NCI staff to ensure timely preparation and submission of reports and publications Oversee the fiscal and budgetary activities of the SPORE Coordinate data control quality assurance issues in conjunction with the Internal Scientific Advisory Committee and the Biostatistics and Data Management Core (Core C) Coordinate activities associated with clinical trials, e.g., designs, approval by regulatory bodies, implementation, and eligibility and assignment of patients to different studies Provide oversight and support for the Biostatistics and Data Management Core (Core C) and the Pathology and Tissue Core (Core B) Coordinate meetings of the [Executive Committee, the Internal and External Scientific Advisory Committees, monthly investigator meetings, quarterly research meetings, lectures, and symposia Administer the Developmental Research Program and the Career Development Program Administer the activities of the Patient Advocates Ensure compliance with and improvement of policies for recruitment of women and minorities Coordinate with other Leukemia SPORE programs and investigators, and other organ-site SPORE programs, to promote communications and integration, through sponsoring a yearly SPORE conference, and distribute materials, electronic communications and progress reports Organize seminars to bring to M. D. Anderson consultants and speakers;sponsor a yearly conference on Translational Research in Leukemia

Public Health Relevance

(See InstrLctions): The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in leukemia.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA100632-12
Application #
8753759
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2014
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77030
Issa, Jean-Pierre; Garcia-Manero, Guillermo; Huang, Xuelin et al. (2015) Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121:556-61
Huang, Xuelin; Ning, Jing; Wahed, Abdus S (2014) Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33:2363-78
Yousefzadeh, Matthew J; Wyatt, David W; Takata, Kei-Ichi et al. (2014) Mechanism of suppression of chromosomal instability by DNA polymerase POLQ. PLoS Genet 10:e1004654
Grunwald, Michael R; Tseng, Li-Hui; Lin, Ming-Tseh et al. (2014) Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant 20:1989-95
Su, Xiaoping; Malouf, Gabriel G; Chen, Yunxin et al. (2014) Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5:9864-76
Chae, Young Kwang; Dimou, Anastasios; Pierce, Sherry et al. (2014) The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma 55:2822-9
Konig, Heiko; Levis, Mark (2014) Is targeted therapy feasible in acute myelogenous leukemia? Curr Hematol Malig Rep 9:118-27
Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram et al. (2014) Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 123:94-100
Bottoni, Arianna; Calin, George A (2014) MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microrna 2:158-64
Zhang, Yun; Xiong, Shunbin; Li, Qin et al. (2014) Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233:380-91

Showing the most recent 10 out of 222 publications